Transplanting patients with HLA antibodies who, when and how

Chaired by Nizam Mamode
The management of sensitised patients can be challenging. To advise patients on their different options, clinicians require an understanding of the laboratory analysis of HLA antibodies and interpretation of the significance of these results in the context of the individual patient. Complex interventions may be required to modulate antibody profiles prior to transplantation, including the use of novel immunosuppressants.
This webinar provides a review of the current literature to describe current approaches to this patients group.
Educational objectives:
1. To explain current strategies for measuring and classifying HLA antibodies.
2. To review current variation in practice across Europe.
3. How we can we risk stratify patients
4. To describe desensitisation strategies.
5. To reflect on outcomes following HLAi transplantation, compared to compatible transplantation and continuing with dialysis.
6. What is the place of Kidney Sharing Schemes/Paired Exchange Programmes
7. To determine which topics are important to consider in these 6 areas, with a view to guideline formation
organised by TLJ 2.0 WORKSTREAM 06 - HLA desensitization
This workstream focuses on discussing the potential recipients with otherwise suitable donors who are relegated to the ever-expanding deceased-donor waiting list because of preformed human leukocyte antigen (HLA) antibodies (HLA sensitization) which may be acquired via pregnancy, transfusion, and/or prior transplant.
Kindly supported by an unrestricted grant from Hansa Biopharma
This is part of the TLJ 2.0 PREPARATORY WEBINARS
Designed to promote discussion and interaction before the meeting, TLJ 2.0 is a comprehensive 360 experience that features a series of complimentary preparatory webinars.
tlj-esot.org/
#transplantation #education #ESOT4edu #ESOTTLJ